Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trial

被引：0
|
作者：
Warren, Richard B. [1 ]
Augustin, Matthias [2 ]
Gottlieb, Alice B. [3 ]
Duffin, Kristina Callis [4 ]
Ciaravino, Valerie [5 ]
Cioffi, Christopher [6 ]
Peterson, Luke [6 ]
Blauvelt, Andrew [7 ]
机构：
[1] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[2] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Univ Utah, Dept Dermatol, Salt Lake City, UT USA
[5] UCB Pharma, Colombes, France
[6] UCB Pharma, Raleigh, NC USA
[7] Oregon Med Res Ctr, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27373
引用
收藏
页码：AB138 / AB138
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
  • [32] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
    Leonardi, C.
    Leutz, A.
    Blauvelt, A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Cameron, G. S.
    Erickson, J.
    Zhao, F.
    Shrom, D. S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [33] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [34] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
    Kern, Johannes S.
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 19
  • [35] Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
    Feldman, Steven R.
    Gottlieb, Alice B.
    Soung, Jennifer
    Augustin, Matthias
    Gisondi, Paolo
    Peterson, Luke
    Vanvoorden, Veerle
    Ciaravino, Valerie
    Gomez, Natalie Nunez
    Warren, Richard B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
  • [36] Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial
    Augustin, Matthias
    Langley, Richard G.
    Warren, Richard B.
    Lebwohl, Mark
    Elewski, Boni
    Crowley, Jeffrey
    Warham, Rhys
    Kaspar, Markus
    Wiegratz, Susanne
    Ciaravino, Valerie
    Gottlieb, Alice B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB184 - AB184
  • [37] Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicentre, randomised, double-blinded phase 3b BE RADIANT trial
    Shumack, Stephen
    Blauvelt, Andrew
    Iversen, Lars
    McBride, Sandy
    Gooderham, Melinda
    Staubach-Renz, Petra
    Yamauchi, Paul
    Staelens, Fabienne
    Vanvoorden, Veerle
    White, Katy
    Gisondi, Paolo
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 17 - 18
  • [38] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Lebwohl, Mark
    Ghoreschi, Kamran
    Strober, Bruce
    Eyerich, Kilian
    Cather, Jennifer
    Wang, Maggie
    Cioffi, Christopher
    Deherder, Delphine
    Staelens, Fabienne
    Gomez, Natalie Nunez
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB145 - AB145
  • [39] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Spelman, Lynda
    Eyerich, Kilian
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 14 - 14
  • [40] Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
    Thaci, Diamant
    Vender, Ron
    de Rie, Menno A.
    Conrad, Curdin
    Pariser, David M.
    Strober, Bruce
    Vanvoorden, Veerle
    Wang, Maggie
    Madden, Cynthia
    de Cuyper, Dirk
    Kimball, Alexa B.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (01) : 22 - 31
12345